Nutritional status and lipid profile in HIV-infected adults

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 15, Issue 4, 2015, Pages 302-307

  Stambullian, M ^a,b   Feliu, M S ^a   Cassetti, L I ^b   Slobodianik, N H ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Helios Salud ^*  (Argentina)

Author keywords

Adults; Apolipoprotein B; HIV infection; Lipids; Non HDL cholesterol; Obesity; Overweight

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; BODY MASS; COLORIMETRY; CROSS-SECTIONAL STUDY; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNODIFFUSION; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; OBESITY; TURBIDIMETRY; ADVERSE EFFECTS; ARGENTINA; BLOOD; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COMPLICATION; DIET; HIV INFECTIONS; HYPERLIPIDEMIAS; LIFESTYLE; MIDDLE AGED; OVERWEIGHT; PREVALENCE; RISK FACTOR;

ADULT; ANTI-HIV AGENTS; ARGENTINA; BIOMARKERS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIET; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; HYPERLIPIDEMIAS; LIFE STYLE; LIPIDS; MALE; MIDDLE AGED; NUTRITIONAL STATUS; OBESITY; OVERWEIGHT; PREVALENCE; RISK FACTORS;

EID: 84959498886     PISSN: 18715303     EISSN: 22123873     Source Type: Journal    
DOI: 10.2174/1871530315666150907111120     Document Type: Article

References (40)

1. Carr, A.; Cooper, D. Adverse effects of antiretroviral therapy. Lancet, 2000, 356, 1423-1429.
2. Calza, L.; Masetti, G.; Piergentili, B.; Trapani, F.; Cascavilla, A.; Manfredi, R.; Colangeli, V.; Viale, P.: Prevalence of diabetes mellitus, hyperinsulinaemia and metabolic syndrome among 755 adult patients with HIV-1 infection. Int. J. STD AIDS, 2011, 22(1), 43-45.
3. Blanco, F.; San Roman, J.; Vispo, E.; Lòpez, M.; Salto, A.; Abad, V.; Soriano, V. Management of metabolic complications and cardiovascular risk in HIV-Infected patients. AIDS Rev., 2010, 12, 231-241.
4. Grinspoon, S.; Carr, A.: Cardiovascular risk and body fat abnormalities in HIV-infected adults. N. Engl. J. Med., 2005, 352, 48-62
5. Fields-Gardner, C.; Campa, A. Position of the American Dietetic Association: Nutrition Intervention and Human Immunodeficiency Virus Infection. J. Am. Diet. Assoc., 2010, 110, 1105-1119.
6. Dubè, M.P.; Stein, J.H.; Aberg, J.A.; Fichtenbaum, C.J.; Gerber, J.G.; Tashima, K.T.; Henry W.K.; Currier J.S.; Sprecher, D.; Glesby M.J.; for the Adult AIDS Clinical Trials Group Cardiovascular Subcommittee. Guidelines for the evaluation and management of dyslipemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. CID, 2003, 37, 613-627.
7. Petit, J.M.; Duong, M.; Florentin, E.; Duvillard, L.; Chavanet, P.; Brun, J.M.; Portier, H.; Gambert, P.; Verges, B. Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen: a stable isotope kinetic study. J. Lipid Res., 2003, 44, 692-1697.
8. Sawadogo, H.N.; Koumarè, A.K.; Kabrè, E.; Sakandè, B.; Kondombo, J.C.; Barro, N.; Traorè, A.; Sawadogo, M.; Simpore, J. Sakande, J. Lipoprotein (a) profile in HIV-1 infected patients treated with highly active antiretroviral therapy (HAART). Biokemistri, 2013, 25(3), 108-112.
9. Meisinger, C.; Loewel, H.; Mraz, W.; Koenig, W. Prognostic value of apolipoprotein B and A-1 in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur. Heart J., 2005, 26(3), 271-278.
10. Sniderman, A.; Williams, K.; de Graaf, J. Non-HDL C equals apolipoprotein B: except when it does not! Curr. Opin. Lipidol., 2010, 21(6), 518-524
11. Davidson, M.H.; Ballantyne, C.M.; Jacobson, T.A.; Bittner, V.A.; Braun, L.T.; Brown, A.S.; Brown, W.V.; Cromwell, W.C.; Goldberg, R.B.; McKenney, J.M.; Remaley, A.T.; Sniderman, A.D.; Toth, P.P.; Tsimikas, S.; Ziajka, P.E.; Maki, K.C.; Dicklin, M.R. Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. J. Clin. Lipidol., 2011, 5(5), 338-367.
12. Schmitz, M.; Michl, G.M.; Bogner, J.; Bogner, J.; Bedynek, A.; Seidel, D.; Goebel, F.D.; Demant, T. Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. JAIDS, 2001, 26, 225-235.
13. Bucher, H.; Reichter, W.; Glass, T.R.; Magenta, L.; Wang, Q.; Cavassini, M.; Vernazza, P.; Hirschel, B.; Weber, R.; Furrer, H.; Battegay, M.; Bernasconi, E. Small Dense Lipoproteins, Apolipoprotein B and Risk of Coronary Events in HIV-Infected Patients on Antiretroviral Therapy: The Swiss HIV Cohort Study. J. Acquir. Immune. Defic., 2012, 60(2), 135-142.
14. World Health Organization. Global Database on Body Mass Index. Available at: http://apps.who.int/bmi/index.jsp?introPage=intro_3.html. (Accessed May 23, 2014).
15. National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of the High Blood Cholesterol in Adults. Executive Summary of the third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). JAMA, 2001, 285(19), 2486-2497.
16. Sniderman, A.D. Applying apo B to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithmic. Curr. Opin. Lipidol., 2004, 15, 433-438.
17. Fibrinogen Studies Collaboration. Plasma Fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality. An individual participant meta-analysis. JAMA, 2005, 294(14), 1799-1809.
18. Myers, G.L.; Rifai, N.; Tracy, R.P.; Roberts, W.L.; Alexander, R.W.; Biasucci, L.M.; Catravas, J.D.; Cole, T.G.; Cooper, G.R.; Khan, B.V.; Kimberly, M.M.; Stein, E.A.; Taubert, K.A.; Warnick, G.R.; Waymack, P.P.; CDC; AHA. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease Application to Clinical and Public Health Practice. Report From the Laboratory Science Discussion Group. Circulation, 2004, 110(25), e545-e549.
19. Ferrante, D.; Linetzky, B.; Konfino, J.; King, A.; Virgolini, M.; Laspiur, S. Encuesta Nacional de Factores de Riesgo 2009: evoluciòn de la epidemia de enfermedades crònicas no transmisibles en Argentina. Estudio de corte transversal. Rev. Argen. Salud. Pública., 2011, 2(6), 35-41.
20. Herrarte, M.I.; Palacios, J.F.; Morales, R.E.; Lopez, G.; Barreda, J.; Fuentes, J.M.; Sliwinski, F.; Muralles, D.; Arathoon, E.; Samayoa, B. Nutritional status of people living with HIV/AIDS attending an urban clinic in Guatemala. XVI Int AIDS Conf., 2006. Abstract no. CDB0863.
21. Maia Leite, L.H.; De Mattos Marinho Sampaio, A.B. Progression to overweight, obesity and associated factors after antiretroviral therapy initiation among Brazilian persons with HIV/AIDS. Nutr. Hosp., 2010, 25(4), 635-640.
22. Stambullian, M.; Cassetti, L.I.; Slobodianik N.H. Nutritional Profile of Adult, HIV-Infected Outpatients. PhD Dissertation. School of Pharmacy and Biochemistry: University of Buenos Aires 2011.
23. Ahouada, C.; Ahomadegbè, C.; Akakpo, J.; Bashil, J.; Zannoul, M.; Azon-Kouanoul, A.; Gougounon A.; Adèl, G.; Houngbè, F. Eating habits, lifestyle and their impact on immunologic status of HIV infected patients at the Centre de Traitement Ambulatoire of CNHU-HKM in Cotonou, Benin. 6th IAS Conference, 2011, Abstract no. CDB058.
24. Joy, T.; Keogh, H.M.; Hadigan, C.; Lee, H.; Dolan, S.E.; Fitch, K.; Liebau, J.; Lo, J.; Johnsen, S.; Hubbard, J.; Anderson, E.J.; Grinspoon, S. Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era. AIDS, 2007, 21, 1591-1600.
25. Klassen, K.; Goff, L.M. Dietary intakes of HIV-infected adults in urban UK. Eur. J. Clin. Nutr., 2013, 67(8), 890-893.
26. Badiou, S.; Thiebaut, R.; Aurillac-Lavignolle, V.; Dabis, F.; Laporte, F.; Cristol, J.P.; Mercie, P.; Groupe d’Epidèmiologie Clinique du Sida en Aquitaine (GECSA). Association of non-HDL cholesterol with subclinical atherosclerosis in HIV-positive patients. J. Infect., 2008, 57(1), 47-54.
27. Joy, T.; Keogh, H.M.; Hadigan, C.; Dolan, S.E.; Fitch, K. Relation of Body Composition to Body Mass Index in HIV-Infected Patients With Metabolic Abnormalities. J. Acquir. Immune. Defic. Syndr., 2008, 47, 174-184
28. Naveed Sattar, N.; Williams, K.; Sniderman, A.D. Comparison of the Associations of Apolipoprotein B and Non-High-Density Lipoprotein Cholesterol With Other Cardiovascular Risk Factors in Patients With the Metabolic Syndrome in the Insulin Resistance Atherosclerosis Study. Circulation, 2004, 110, 2687-2693.
29. Pischon, T.; Girman, C.J.; Sacks, F.M.; Rifai, N.; Stampfer, M.J.; Rimm, E.B. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation, 2005, 112(22), 3375-3383.
30. Sniderman, A.D.; Islam, S.; Yusuf, S.; McQueen, M.J. Discordance analysis of Apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. Atherosclerosis, 2012, 225, 444-449.
31. de Carvalho, E.H.; Miranda Filho, D.; Ximenes, R.A.; de Albuquerque, M. F.; de Melo, H.R.; Gelenske, T.; de Medeiros, Z. B.; Montarroyos, U.; Bandeira, F. Prevalence of Hyperapolipoprotein B and Associations with other cardiovascular risk factors among human immunodeficiency virus-infected patients in Pernambuco, Brazil. Metab. Syndr. Relat. Disord., 2010, 8(5), 403-410.
32. Dati, F.; Tate J. Reference Materials for the Standardization of the Apolipoproteins A-I and B, and Lipoprotein(a). eJIFCC; 13(3). Available at: http://www.ifcc.org/ejifcc/vol13no3/130301003.htm. (Accessed Oct 28, 2014)
33. Lanas, F.; Avezum, A.; Bautista, L.E.; Diaz, R.; Luna, M.; Islam, S.; Yusuf, S.; INTERHEART Investigators in Latin America. Risk factors for acute myocardial infarction in Latin America. The INTERHEART Latin American Study. Circulation, 2007, 115, 1067-1074.
34. Madden, E.; Lee, G.; Kotler, D.P.; Wanke, C.; Lewis, C.E.; Tracy, R.; Heymsfield, S.; Shlipak, M.G.; Bacchetti, P.; Scherzer, R.; Grunfeld, C. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS, 2008, 22(6), 707-715.
35. Tien, P.C.; Choi, A.I.; Zolopa, A.R.; Benson, C.; Tracy, R.; Scherzer, R.; Bacchetti, P.; Shlipak, M.; Grunfeld C. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr, 2010, 55(3), 316-322
36. De Luca, A.; de Gaetano Donati, K.; Colafigli, M.; Cozzi-Lepri, A.; De Curtis, A.; Gori, A.; Sighinolfi, L.; Giacometti, A.; Capobianchi, M.R.; D’Avino, A.; Iacoviello, L.; Cauda, R.; D’Arminio Monforte, A. The association of high-sensitivity Creactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study. BMC Infect. Dis., 2013, 13, 414
37. Friis-Møller, N.; Sabin, C.A.; Weber, R.; d’Arminio Monforte, A.; El-Sadr, W.M.; Reiss, P.; Thiebaut, R.; Morfeldt, L.; De Wit, S.; Pradier, C.; Calvo, G.; Law, M.G.; Kirk, O.; Phillips, A.N.; Lundgren, J.D.; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. N. Engl. J. Med., 2003, 349(21), 1993-2003.
38. Remick, J.; Georgiopoulou, V.; Marti, C.; Ofotokun, I.; Kalogeropoulos A.; Lewis, W.; Butler, J. Heart Failure in Patients with Immunodeficiency Virus Infection. Circulation, 2014, 129(17), 1781-1789.
39. Fitch, K.V.; Anderson, E.J.; Hubbard, J.L. Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS, 2006, 20(14), 1843-50.
40. Loonam, C.R.; Mullen, A. Nutrition and HIV-associated lipodystrophy syndrome. Nutr. Res. Rev., 2012, 25(2), 267-287.